EMA Environmental Risk Assessment (ERA) Guideline 2024: Advanced Technical Requirements For EU Pharmaceutical Market Access

Introduction: A Paradigm Shift in Environmental Compliance for Pharmaceuticals

The European Medicines Agency has fundamentally reshaped environmental compliance with its updated ERA Guideline (effective September 2024).

This is not an incremental update, it represents a system-level transformation in how environmental risks are assessed, documented, and regulated across the pharmaceutical lifecycle.

What is the EMA ERA Guideline 2024 for pharmaceuticals?
The 2024 Environmental Risk Assessment (ERA) Guideline by the European Medicines Agency requires comprehensive environmental evaluation of all human medicinal products, including generics and biosimilars. It introduces advanced PEC modelling, mandatory Phase II triggers, detailed ecotoxicology data, and strengthened PBT/vPvB assessment aligned with EU sustainability frameworks.

Key Drivers Behind the Update

• Rising pharmaceutical residues in aquatic environments 
• Antimicrobial resistance (AMR) linked to environmental exposure  
• Increasing scrutiny under ESG and sustainability frameworks 
• Alignment with EU policy frameworks such as: 
  • European Green Deal 
  • Zero Pollution Action Plan 
  • REACH Regulation 

Strategic Impact

Environmental compliance is now:

• A core regulatory requirement 
• A market access enabler 
• A competitive differentiator 

Expanded Regulatory Scope: ERA Is Now Mandatory Across All Product Types

The 2024 ERA guideline significantly expands applicability.

Applies To

• New Chemical Entities (NCEs) 
• Generics and hybrid medicinal products 
• Biosimilars and biologics 
• Fixed-dose combinations 
• Line extensions and reformulations 
• Post-authorization variations increasing environmental exposure  
• High-volume APIs 

Key Change

ERA is now mandatory for nearly all Marketing Authorization Applications (MAAs) across:

• Centralized procedure 
• Decentralized procedure 
• Mutual Recognition Procedure (MRP) 
• National procedures 

Not Eligible for Waivers

• APIs with PBT/vPvB characteristics 
• Antibiotics and antiparasitic agents 
• Endocrine-active compounds 
• Persistent and poorly degradable substances 
• APIs with complex or active metabolites 

ERA Dossier Requirements: Module 1.6 (eCTD) Reinforcement

Applicants must submit a complete ERA dossier in Module 1.6 of the electronic Common Technical Document (eCTD).

Key Expectations

• Structured ERA report aligned with EMA format 
• Full traceability of raw data and analytical methods 
• Integration of environmental fate, exposure, and hazard data 
• Scientific justification for all assumptions and waivers 

Stepwise ERA Methodology: Advanced Phase I & Phase II Framework

Phase I: Enhanced PEC Modelling & Exposure Assessment

Phase I focuses on predicting environmental exposure using refined models.

Core Technical Inputs

• API daily dose and consumption modelling 
• Regional usage patterns 
• Excretion pathways (renal, biliary, unchanged API) 
• Sewage treatment plant (STP) removal efficiency 
• Physicochemical parameters (Koc, Kow, pKa) 
• Environmental dilution modelling 

Key Output

• Predicted Environmental Concentration in surface water (PECsw) 

Automatic Triggers for Phase II

Phase II is mandatory when:

• PECsw > 0.01 µg/L 
• API shows antimicrobial or endocrine activity 
• Poor biodegradability (e.g., DT50 > 120 days) 
• Structural alerts for bioaccumulation 
• AMR-related risk indicators 

Phase II: Comprehensive Environmental Fate & Hazard Characterization

Phase II requires a data-rich, multi-dimensional dataset.

Environmental Fate & Transformation Studies

Conducted under OECD frameworks:

• OECD 301 
• OECD 302 
• OECD 308 
• OECD 307 
• OECD 305 

Additional Requirements

• Identification of transformation products 
• Advanced analytical techniques (LC-MS/MS) 
• Multi-compartment environmental modelling 

Ecotoxicological Endpoints

Mandatory acute and chronic studies include:

• OECD 201 
• OECD 202 
• OECD 211 
• OECD 203 
• OECD 210 
• OECD 218 
• OECD 222 
• OECD 209 

Compliance Requirements

• GLP-compliant studies 
• Validated analytical methods 
• Full raw data traceability 

Reinforced PBT/vPvB Evaluation: A Regulatory Priority

The guideline introduces stringent criteria for:

Persistence (P)

• DT50 > 120 days in soil or sediment 

Bioaccumulation (B)

• BCF > 2,000 

Toxicity (T)

• Chronic NOEC thresholds 

Additional Requirements

• vPvB classification (very persistent, very bioaccumulative) 
• Trophic Magnification Factor (TMF) calculations 
• Multi-compartment kinetic modelling 
• Metabolite persistence assessment 

Regulatory Expectations

• Environmental monitoring proposals 
• Risk mitigation measures (SmPC Section 6.6) 
• Lifecycle environmental risk strategies 

Advanced Data Transparency & Digital Traceability

The 2024 guideline significantly strengthens data transparency requirements.

Mandatory Components

• Systematic Literature Reviews (SLR) aligned with PRISMA 
• Integration with global databases: 
  • European Chemicals Agency 
  • United States Environmental Protection Agency 
• Scientific justification for waivers 
• Full audit trail of data sources and methodologies 

Outcome

• Reduced regulatory queries 
• Improved scientific defensibility 
• Faster review timelines 

Strengthened 3Rs Framework: Ethical Environmental Testing

The guideline reinforces EU ethical principles:

Replacement

• QSAR/QSPR models 
• New Approach Methodologies (NAMs) 
• In-silico environmental modelling 

Reduction

• Read-across approaches 
• Bridging studies 

Refinement

• Optimized study design 
• Reduced organism use 

Regulatory Expectation

Every animal study must be scientifically justified and necessary.

Comparison Table: Previous ERA vs EMA ERA Guideline 2024

Key Challenges for Pharmaceutical Companies

Regulatory Complexity

• Multi-layered environmental data requirements 

Data Gaps

• Limited historical ecotoxicology data for legacy APIs 

Cost & Timeline Pressure

• Extensive testing increases development timelines 

Cross-Functional Integration

• Requires collaboration across R&D, regulatory, toxicology, and sustainability teams 

Data-Driven ERA: The Future of Environmental Compliance

Modern ERA strategies increasingly leverage:

Advanced Technologies

• Predictive environmental modelling 
• AI-driven exposure simulation 
• Digital twin ecosystems 
• High-throughput ecotoxicology screening 

Benefits

• Faster decision-making 
• Reduced testing burden 
• Improved regulatory alignment 
• Enhanced sustainability performance 

Strategic Compliance Framework for EU Market Access

1. Early ERA Integration

• Initiate environmental assessment in early development 

2. Robust Data Strategy

• Generate complete, high-quality datasets 

3. Risk-Based Decision Making

• Prioritize high-risk APIs 

4. Cross-Functional Alignment

• Integrate regulatory, environmental, and R&D teams 

5. Continuous Regulatory Monitoring

• Track evolving EMA expectations and EU policies 

Maven Regulatory Solutions: Your ERA Compliance Partner

Maven Regulatory Solutions provides expert support for ERA compliance across EU markets.

Our Expertise

Environmental Risk Assessment

• PEC modelling 
• PBT/vPvB evaluation 
• Ecotoxicology strategy 

Regulatory Documentation

• Module 1.6 ERA dossier preparation 
• eCTD structuring 

Data Strategy

• Gap analysis and study planning 
• OECD study coordination 

Submission & Review Support

• Query response management 
• Regulatory authority interaction 

Preparing for EMA ERA compliance in 2025?

• Build robust environmental risk assessment strategies
• Aligning with EMA 2024 guideline expectations
• Reduce regulatory delays and deficiency risks
• Strengthening ESG and sustainability positioning
• Accelerate EU market access

Partner with Maven Regulatory Solutions today

Conclusion: ERA Compliance Is Now a Strategic Imperative

The European Medicines Agency ERA Guideline 2024 represents a major evolution in pharmaceutical regulation.

Success now requires:

• Advanced environmental modelling 
• Comprehensive ecotoxicological datasets 
• Strong PBT/vPvB assessments 
• Transparent, traceable documentation 
• Lifecycle environmental risk integration 

Companies that proactively adapt will achieve:

• Faster approvals 
• Reduced regulatory risk 
• Stronger sustainability credentials 
• Competitive advantage in EU markets 

Frequently Asked Questions

1. What is ERA in pharmaceuticals?

Environmental Risk Assessment evaluates the impact of drugs on the environment.

2. Who enforces the ERA guideline?

The European Medicines Agency.

3. Is ERA mandatory for generics?

Yes, under the 2024 update.

4. What triggers Phase II?

PEC thresholds, persistence, endocrine activity, and AMR risks.

5. What are PBT substances?

Persistent, Bioaccumulative, and Toxic substances.

6. Are animal studies required?

Only when justified under the 3Rs framework.

7. What is Module 1.6?

The ERA section in the eCTD submission.

8. Why is ERA important for market access?

It is now a mandatory requirement for EU approval.